Iambic Therapeutics
PrivateLast Round
Series B
Sep 9, 2026
Total Funding Raised
$253M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Iambic Therapeutics is a biotechnology company that develops an AI-driven drug discovery platform to create novel medicines for cancer and other diseases.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Iambic Therapeutics Comparables
Compare Iambic Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Genesis Therapeutics | 88% | |
| Valo Health | 87% | |
| Terray Therapeutics | 87% |
Iambic Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 9, 2026 | ||||
| Early Stage VC | Apr 8, 2026 | ||||
| VC Round | Nov 10, 2025 | ||||
| Series B Extension | Jun 18, 2024 | ||||
| Series B | Oct 3, 2023 | ||||
Series A | Jul 14, 2021 |
Key People
Founding team and executive leadership
Iambic Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B |
| OrbiMed | Series B, Series A |
| Catalio Capital Management | Series B, VC Round, Series A |
| Freeflow Ventures | VC Round |
| Sequoia Capital | Series B, Series A, VC Round |
| Abingworth | Series B Extension, VC Round, Series B |
| Shanda Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 23, 2026
Grew 17% QoQ, adding 27 employees.
- Sep 9, 2026
$66M round closed.
Recent news
Latest coverage and updates
- has_revenueOct 9, 2026
Iambic Therapeutics, Inc. reports $12.8M in revenue for the six months ended Jun 30th '26, alongside a US$50.1 million net loss.
- is_developingOct 9, 2026
Iambic Therapeutics, Inc. plans to continue developing its AI platform with $20m in IPO proceeds
- has_revenueOct 9, 2026
Iambic Therapeutics, Inc. reports $9.4M in collaboration revenue for 2025 in California
- is_developingSep 22, 2026
Iambic Therapeutics, Inc. is developing two earlier-stage programs designated IAM217 and IAM-C1 on Sep 21st '26.
- launchesSep 21, 2026
Iambic Therapeutics, Inc. launches next version of Enchant model.
Iambic Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Iambic Therapeutics's valuation, stock price, and market status.
Is Iambic Therapeutics a public or private company?
Iambic Therapeutics is a private company.
What is the current stock price of Iambic Therapeutics?
Iambic Therapeutics is a private company, so its shares have no public market price. Caplight tracks Iambic Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Iambic Therapeutics worth (valuation)?
Valuation information for Iambic Therapeutics is not publicly available.
Can I buy Iambic Therapeutics stock?
Iambic Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Iambic Therapeutics's last funding round?
Iambic Therapeutics's most recent funding round was Series B on September 9, 2026.
Who are the main investors in Iambic Therapeutics?
Key investors in Iambic Therapeutics include Catalio Capital Management, Abingworth, Mubadala Capital, Exor Ventures, Coatue Management.
Will Iambic Therapeutics IPO soon?
No public IPO plans have been announced for Iambic Therapeutics.
How can I track Iambic Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Iambic Therapeutics's shares on secondary markets.